Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Migraine drugs blocking CGRP/RAMP1 reduce colorectal and stomach tumor growth in studies, offering a fast-track treatment possibility.
Australian researchers have found that nerve signaling molecules, particularly CGRP and its receptor RAMP1, drive the growth of colorectal and stomach cancers.
The study, published in BMJ Oncology, shows these neural components help tumors survive, grow, and evade the immune system.
Blocking CGRP or RAMP1—using migraine drugs already approved for human use—reduced tumor growth in experiments, suggesting a potential new treatment strategy.
The findings highlight a promising, faster path to clinical trials by repurposing existing medications.
3 Articles
Los fármacos para la migraña que bloquean CGRP/RAMP1 reducen el crecimiento de tumores colorrectales y estomacales en los estudios, ofreciendo una posibilidad de tratamiento acelerado.